Key result
Semaglutide boosts quality of life clinical summary scores by ~7 points over placebo at 52 weeks.
Why the study?
Does semaglutide 2.4 mg improve the KCCQ Clinical Summary Score and reduce body weight compared to placebo in patients with obesity-related HFpEF and type 2 diabetes?
RCT
Placebo-controlled
Does semaglutide 2.4 mg improve the KCCQ Clinical Summary Score and reduce body weight compared to placebo in patients with obesity-related HFpEF and type 2 diabetes?
In phase 3 trial registry results, semaglutide 2.4 mg produced significantly greater improvements in heart failure-related symptoms (KCCQ Clinical Summary Score) and weight loss at 52 weeks compared to placebo in patients with obesity-related HFpEF and type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I think that uh one of the things that we really want to do is convince clinicians and part of this trial was doing that that obesity is not just a bystander. it's one of the principal. causes of heart failure with preserved ejection fraction. and I think this proves. it”
“Obesity forms a 'common soil' that can lead to the development of heart failure with preserved ejection fraction and type 2 diabetes, and patients living with both conditions suffer from an especially high symptom burden but have few available treatment options. Today's results, especially when combined with those from the STEP-HFpEF trial, open a new chapter of targeting obesity as a new and effective treatment strategy in patients with obesity-related HFpEF, both with and without diabetes.”
“This is a really important message for the field. Of course, weight loss is important. That is one of the factors behind what we are observing.”
Supports semaglutide for symptom relief in obese HF; extends GLP-1 evidence to KCCQ gains in phase 3.
Registry results from a Novo Nordisk phase 3 trial report a larger increase in the KCCQ Clinical Summary Score and greater weight loss with semaglutide 2.4 mg than placebo at 52 weeks. At week 52, the KCCQ Clinical Summary Score rose by 14.4 with semaglutide 2.4 mg and by 7.6 with placebo (p <0.0001). Body weight fell in both groups. The mean percentage change was -10.2 with semaglutide and -3.2 with placebo (p <0.0001). The record reports symptom and weight outcomes only. It gives no hospitalisation, death or safety data in this extract. Online version: https://www.diabesityrounds.com/a/semaglutide-2-4-mg-in-obesity-related-hfpef-with-type-2-diabetes-phase-3-registr
No takes yet. Share an insight, caveat, or question.
Diabesity Rounds (2026) conducted an RCT in Obesity-related HFpEF with type 2 diabetes. Semaglutide vs. Placebo was evaluated on Change in KCCQ Clinical Summary Score and percentage change in body weight at 52 weeks (p=<0.0001). Semaglutide increased the quality of life Clinical Summary Score and reduced body weight compared to placebo at 52 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: